Kaposi sarcoma
Information
- Disease name
- Kaposi sarcoma
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04742387 | Active, not recruiting | Assessment of Bone Mineral Density in People Living With HIV and KSHV Associated Malignancies: A Retrospective Longitudinal Analysis | February 4, 2021 | December 31, 2024 | |
| NCT02595866 | Active, not recruiting | Phase 1 | Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer | April 4, 2016 | October 11, 2024 |
| NCT02659930 | Active, not recruiting | Phase 1 | Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma | January 13, 2016 | January 1, 2028 |
| NCT03404297 | Completed | N/A | Compression Therapy for Leg Ulcers and Kaposi Sarcoma in Western Kenya | March 1, 2018 | December 31, 2019 |
| NCT03316274 | Completed | Early Phase 1 | Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma | May 7, 2018 | June 30, 2021 |
| NCT03050788 | Completed | N/A | Smartphone Confocal Microscopy for Diagnosing Kaposi's Sarcoma | March 10, 2017 | February 28, 2020 |
| NCT03157167 | Completed | Phase 1 | An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS) | December 1, 2017 | March 30, 2020 |
| NCT03296553 | Completed | Phase 2 | Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial. | October 1, 2015 | August 26, 2019 |
| NCT03160183 | Completed | Investigating Chemotherapy Treatments, Response and Subsets of HIV-associated Kaposi Sarcoma in Malawi | September 2016 | October 1, 2020 | |
| NCT00395278 | Completed | Development of Serologic Assays for Human Herpes Virus-8 | October 30, 2006 | December 10, 2020 | |
| NCT01495598 | Completed | Phase 1/Phase 2 | Pomalidomide for Kaposi Sarcoma in People With or Without HIV | January 10, 2012 | May 17, 2022 |
| NCT06445166 | Not yet recruiting | Phase 2 | Propranolol for the Treatment of Kaposi Sarcoma in Adults | September 30, 2024 | September 30, 2027 |
| NCT05411237 | Not yet recruiting | Phase 3 | Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma | March 15, 2024 | September 2028 |
| NCT05797662 | Not yet recruiting | Phase 2 | A Study of Propranolol to Treat Kaposi Sarcoma | July 1, 2025 | August 1, 2029 |
| NCT05846724 | Not yet recruiting | Phase 2 | Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi Sarcoma | February 1, 2024 | February 1, 2030 |
| NCT06004011 | Not yet recruiting | N/A | AYAHIV Role-based Responsibilities for Oncology-focused Workforce (ARROW) | July 2024 | July 2027 |
| NCT03993106 | Recruiting | Phase 2 | A Study of sEphB4-HSA in Kaposi Sarcoma | September 17, 2020 | June 2025 |
| NCT04303117 | Recruiting | Phase 1/Phase 2 | NHS-IL12 Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma | July 13, 2020 | December 1, 2028 |
| NCT04305691 | Recruiting | Phase 2 | Trial of Ixazomib for Kaposi Sarcoma | November 7, 2023 | May 30, 2026 |
| NCT05081141 | Recruiting | HHV8 and Solid Organ Transplantation | September 15, 2021 | December 31, 2025 | |
| NCT05329792 | Recruiting | Phase 2 | L19IL2/L19TNF in Skin Cancer Patients | March 9, 2023 | December 2024 |
| NCT05859074 | Recruiting | Phase 1 | A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer | May 4, 2023 | May 4, 2028 |
| NCT05663502 | Recruiting | Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers | May 10, 2023 | August 31, 2035 | |
| NCT06375122 | Recruiting | Natural History Study of Kaposi Sarcoma | May 15, 2024 | December 31, 2036 | |
| NCT02408861 | Recruiting | Phase 1 | Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | October 21, 2015 | July 1, 2024 |
| NCT04902443 | Recruiting | Phase 1 | Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV | December 10, 2021 | December 1, 2026 |
| NCT04941274 | Recruiting | Phase 1/Phase 2 | Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma | September 29, 2021 | June 1, 2028 |
| NCT02080416 | Terminated | Early Phase 1 | Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors | July 2014 | February 2016 |
| NCT04893018 | Terminated | Phase 1 | NT-I7 for Kaposi Sarcoma in Patients With or Without HIV | May 23, 2022 | December 15, 2023 |
| NCT01412515 | Terminated | Phase 2 | A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma | June 2008 | May 2011 |
| NCT04065152 | Unknown status | Phase 2 | Phase II Multicenter Study of Talimogene Laherparepvec in Classic or Endemic Kaposi Sarcoma | January 1, 2021 | February 1, 2024 |
| NCT03469804 | Unknown status | Phase 2 | Phase II Multicentric Study of Pembrolizumab in Classic or Endemic Kaposi's Sarcoma | July 1, 2018 | September 20, 2020 |
| NCT02229981 | Withdrawn | Phase 1/Phase 2 | Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma | July 2014 | December 2019 |
- OrphaNumber from OrphaNet (Orphanet)
- 33276
- ICD10 preferred id (Insert disease from ICD10)
- D0002024
- ICD10 class code (Insert disease from ICD10)
- C46